PulmoBioMed offers the PBM‑Hale™ system, a non‑invasive device that captures exhaled gases and aerosolised particles directly from the deep lung using a patented, closed‑system sampling chamber. The technology provides highly reproducible, contamination‑free samples ready for standard analytical workflows, supporting clinical diagnostics, respiratory research, and pharmaceutical inhalation studies.
Funding
$883.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Accurate analysis of deep‑lung exhaled gases and aerosolised particles is difficult with existing collection methods, which often involve invasive procedures, inconsistent sampling, and risk of contamination or sample loss. This limits reliable diagnostics and research into respiratory diseases.
Solution
PulmoBioMed’s PBM‑Hale™ provides a non‑invasive device that captures exhaled gas and aerosolised samples exclusively from the deep lung. The system uses a patented sampling pathway that isolates the lower respiratory tract, ensuring highly reproducible collections without external contamination or loss of material. Samples are sealed and ready for downstream analytical workflows, supporting both clinical diagnostics and research investigations. The technology is protected by international patents and is registered with the US FDA as a Firm Establishment, underscoring its regulatory compliance and quality standards.
Target Audience
Primary customers are pulmonology clinics, respiratory research laboratories, and pharmaceutical companies conducting inhalation studies.
Features
- Dedicated deep‑lung sampling chamber that separates lower airway exhalate from ambient air
- Fully non‑invasive collection process suitable for routine clinical use
- Closed‑system design eliminates cross‑contamination and prevents sample degradation
- High reproducibility across repeated measurements, enabling longitudinal studies
- Patented technology (WO2017153755, WO2019053423) with FDA Firm Establishment registration
- Compatible with standard gas‑analysis and aerosol‑characterization platforms